Information Provided By: 
Fly News Breaks for January 10, 2018
EPZM
Jan 10, 2018 | 07:47 EDT
Morgan Stanley analyst Andrew Berens started Epizyme with an Overweight rating and $20 price target, stating that the company's key asset, tazemetostat, has shown sufficient activity and tolerability to warrant studying in combination with existing regimens. The company is also testing tazemetostat in a number of rare solid tumors, which could represent the fastest initial pathway to approval, Berens tells investors.
News For EPZM From the Last 2 Days
There are no results for your query EPZM
